Recombinant Human DCBLD2/ESDN Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human DCBLD2/ESDN Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit proliferation/survival of IEC‑18 rat small intestinal epithelial cells. The ED₅₀ for this effect is 0.7-2.8 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived human DCBLD2/ESDN protein
  Gln67-Ala528, with a C-terminal 6-His tag
• Accession #: Q96PD2
• N-terminal Sequence: No results obtained: Gln67 predicted, sequencing might be blocked
• Protein/Peptide Type: Recombinant Proteins
• Gene: DCBLD2
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 51.9 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 80-90 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 300 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human DCBLD2/ESDN Protein, CF

• CLCP1
• CLCP11700055P21Rik
• CUB, LCCL and coagulation factor V/VIII-homology domains protein 1
• DCBLD2
• discoidin, CUB and LCCL domain containing 2
• discoidin, CUB and LCCL domain-containing protein 2
• Endothelial and smooth muscle cell-derived neuropilin-like protein
• ESDN
• ESDNcoagulation factor V/VIII-homology domains protein 1

Background

DCBLD2 (discoidin, CUB, and LCCL domain containing protein 2), also known as CLCP1 and ESDN, is a 100-130 kDa glycoprotein that bears structural resemblance to the Neuropilin family of molecules. Mature human DCBLD2 is a type I transmembrane protein that consists of a 462 amino acid (aa) extracellular region (ECD), a 21 aa transmembrane segment, and a 226 aa cytoplasmic domain (1, 2). Within the ECD, human DCBLD2 shares approximately 88% aa sequence identity with mouse and rat DCBLD2. Alternative splicing generates an isoform that contains a 14 aa insertion in the cytoplasmic domain. DCBLD2 is expressed on vascular smooth muscle cells (VSMC), particularly in regions of arteriosclerosis and vascular injury (2, 3). It is up‑regulated on PDGF-BB stimulated VSMC and inhibits PDGF‑BB induced VSMC proliferation and migration (2‑4). It is also expressed on platelets and inhibits clot formation in a zebrafish model of thrombosis (5). Compared to normal tissue, DCBLD2 expression is down‑regulated in some gastric and neuroendocrine tumors but is up‑regulated in some metastatic lung cancers (1, 6, 7). It can be tyrosine phosphorylated in response to EGF R signaling and can inhibit colony formation and tumor cell invasiveness (6, 8, 9). Its direct association with Semaphorin 4B induces DCBLD2 degradation (10).

1. Koshikawa, K. et al. (2002) Oncogene 21:2822.
2. Kobuke, K. et al. (2001) J. Biol. Chem. 276:34105.
3. Sadeghi, M.M. et al. (2007) Am. J. Transplant. 7:2098.
4. Guo, X. et al. (2009) J. Biol. Chem. 284:29376.
5. O’Connor, M.N. et al. (2009) Blood 113:4754.
6. Kim, M. et al. (2008) Mol. Cancer Res. 6:222.
7. Hofsli, E. et al. (2008) Br. J. Cancer 99:1330.
8. Chen, Y. et al. (2007) Proteomics 7:2384.
9. Orso, F. et al. (2008) FASEB J. 22:2702.
10. Nagai, H. et al. (2007) Oncogene 26:4025.

Bioinformatics

• Gene Symbol: DCBLD2
• Uniprot:
  • Q96PD2(Human)